View Cart (0 items)

Pharmaceutical

Teva to end cancer, women's health research

Generic drugmaker Teva Pharmaceutical Industries Ltd. has decided to stop research and development in a number of areas, including oncology and women's health, as part of efforts to cut costs.
Read More

Antibiotics, heavy metals in the environment contribute to resistance

Very low concentrations of antibiotics and heavy metals in the environment contribute to antibiotic resistance, a new Swedish study has demonstrated.
Read More

Consort agrees to $372 million acquisition of Aesica

U.K.-based healthcare company Consort Medical plc announced on Tuesday an agreement to acquire Aesica Pharmaceuticals.
Read More

Pfizer acquires InnoPharma

Pharmaceutical giant Pfizer Inc. has completed its acquisition of InnoPharma Inc., the company announced on Thursday.
Read More

PCI acquires clinical trail services company Biotec

Pharmaceutical packaging services provider PCI has expanded its presence in the European Union with the acquisition of Biotec Services International.
Read More

New heart failure drug could cut deaths by 20%

Swiss pharmaceuticals group Novartis is planning to launch a new drug that has the potential to cut cardiovascular death and admissions to hospital by 20%.
Read More

New facility to research personalized cellular cancer therapies

A new facility to develop personalized cellular cancer therapies will be built by the University of Pennsylvania, funded in part with a $20 million investment from Novartis.
Read More

Global pharmaceutical sales projected to reach $1 trillion in 2014

The outlook for the pharmaceutical industry is bright, according to a new report that identifies a number of positive trends.
Read More

GSK recalls batches of Eye-Mo solution

London-listed pharmaceuticals giant GlaxoSmithKline (GSK) has launched a voluntary recall of several batches of its Eye-Mo Red Eyes Formula Ophthalmic Solution.
Read More

GSK to start clinical trials on new Ebola vaccine

London-listed pharmaceuticals company GlaxoKlineSmith will start clinical safety trials for its experimental Ebola vaccine in the U.S. as early as next week.
Read More